Research Alliance Corporation III’s Oak Hill Bio combination is expected to close in the fourth quarter of 2026, supported by $55,000,000 of PIPE financing. Disclosure controls were ineffective as of September 30, 2026 due to a material weakness.
RACC · Research Alliance Corp III · Documents
Substantial doubt about the company's ability to continue as a going concern.
“This condition raises substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 16, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Research Alliance Corporation III seeks shareholder approval at its November 24, 2026 meeting for a business combination with Oak Hill Bio, which has a $160,000,000 base equity value, plus a $55,000,000 PIPE financing.
Research Alliance Corporation III agreed to acquire OHB Pediatrics Ltd., issue 16,000,000 shares to its shareholders, and raise $55,000,000 through a PIPE financing; the combined company will move to Delaware and become Oak Hill Bio Inc.